These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 35903214)

  • 21. Investment in biosafety and biosecurity: the need for a risk-based approach and systematic reporting of laboratory accidents to mitigate laboratory-acquired infections and pathogen escapes.
    Blacksell SD; Summermatter K; Masuku ZM; Kojima K; Ross E; Harper DR; Hamilton K
    Lancet Microbe; 2023 Nov; 4(11):e854-e855. PubMed ID: 37774730
    [No Abstract]   [Full Text] [Related]  

  • 22. In the Shadow of Biological Warfare: Conspiracy Theories on the Origins of COVID-19 and Enhancing Global Governance of Biosafety as a Matter of Urgency.
    Nie JB
    J Bioeth Inq; 2020 Dec; 17(4):567-574. PubMed ID: 32840850
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Surveillance of laboratory exposures to human pathogens and toxins: Canada 2016.
    Bienek A; Heisz M; Su M
    Can Commun Dis Rep; 2017 Nov; 43(11):228-235. PubMed ID: 29770052
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Biohazards in research laboratories].
    Porru S; Chiappin M; Sfriso N
    G Ital Med Lav Ergon; 2019 Dec; 41(4):359-364. PubMed ID: 32126610
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design and Construction of a Biosafety Level 3 Autopsy Laboratory.
    Nolte KB; Muller TB; Denmark AM; Burstein R; Villalobos YA
    Arch Pathol Lab Med; 2021 Apr; 145(4):407-414. PubMed ID: 33307551
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Marburg biosafety and biosecurity scale (MBBS): a framework for risk assessment and risk communication.
    Dickmann P; Apfel F; Biedenkopf N; Eickmann M; Becker S
    Health Secur; 2015; 13(2):88-95. PubMed ID: 25813975
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improving Biosecurity in Pakistan: Current Efforts, Challenges, and Recommendations on a Multidimensional Management Strategy.
    Khan T; Tanveer F; Muhammad J
    Health Secur; 2021; 19(3):254-261. PubMed ID: 33956522
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Containment of arthropod disease vectors.
    Scott TW
    ILAR J; 2005; 46(1):53-61. PubMed ID: 15644564
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multivariate analyses of risk factors associated with laboratory exposure incidents.
    El Jaouhari M; Atchessi N; Edjoc R; Striha M; Bonti-Ankomah S
    Can Commun Dis Rep; 2022 Jul; 48(7-8):350-355. PubMed ID: 37416113
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The global proliferation of high-containment biological laboratories: understanding the phenomenon and its implications.
    Peters A
    Rev Sci Tech; 2018 Dec; 37(3):857-883. PubMed ID: 30964462
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Meta-analysis to explain unknown causes of the origins of SARS-COV-2.
    Coccia M
    Environ Res; 2022 Aug; 211():113062. PubMed ID: 35259407
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Harmonization of Biosafety and Biosecurity Standards for High-Containment Facilities in Low- and Middle-Income Countries: An Approach From the Perspective of Occupational Safety and Health.
    Maehira Y; Spencer RC
    Front Public Health; 2019; 7():249. PubMed ID: 31572701
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Laboratory Biosafety Considerations of SARS-CoV-2 at Biosafety Level 2.
    Wang K; Zhu X; Xu J
    Health Secur; 2020; 18(3):232-236. PubMed ID: 32522074
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of regulations, safety considerations and physical limitations on research progress at maximum biocontainment.
    Shurtleff AC; Garza N; Lackemeyer M; Carrion R; Griffiths A; Patterson J; Edwin SS; Bavari S
    Viruses; 2012 Dec; 4(12):3932-51. PubMed ID: 23342380
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of biorisk management systems in high containment laboratories, 18 countries in Europe, 2016 and 2017.
    Appelt S; Jacob D; Rohleder AM; Bråve A; Szekely Björndal Å; Di Caro A; Grunow R;
    Euro Surveill; 2020 Sep; 25(36):. PubMed ID: 32914748
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Biosafety in laboratories concerning exposure to biological agents].
    Vonesch N; Tomao P; Di Renzi S; Vita S; Signorini S
    G Ital Med Lav Ergon; 2006; 28(4):444-56. PubMed ID: 17380946
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Survey of laboratory-acquired infections around the world in biosafety level 3 and 4 laboratories.
    Wurtz N; Papa A; Hukic M; Di Caro A; Leparc-Goffart I; Leroy E; Landini MP; Sekeyova Z; Dumler JS; Bădescu D; Busquets N; Calistri A; Parolin C; Palù G; Christova I; Maurin M; La Scola B; Raoult D
    Eur J Clin Microbiol Infect Dis; 2016 Aug; 35(8):1247-58. PubMed ID: 27234593
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lessons to be Learned from Recent Biosafety Incidents in the United States.
    Weiss S; Yitzhaki S; Shapira SC
    Isr Med Assoc J; 2015 May; 17(5):269-73. PubMed ID: 26137650
    [TBL] [Abstract][Full Text] [Related]  

  • 39. State-of-the-art in biosafety and biosecurity in European countries.
    Bielecka A; Mohammadi AA
    Arch Immunol Ther Exp (Warsz); 2014 Jun; 62(3):169-78. PubMed ID: 24819711
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Main Biological Hazards in Animal Biosafety Level 2 Facilities and Strategies for Control.
    Li XY; Xue KN; Jiang JS; Lu XC
    Biomed Environ Sci; 2016 Apr; 29(4):300-4. PubMed ID: 27241742
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.